Zacks Investment Research downgraded shares of SUCAMPO PHARMAC (SCMP) from N/A to NEUTRAL on April 05, 2013, with a target price of $7.10.
Sucampo Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. Sucampo is focused on developing prostones for the treatment of gastrointestinal, respiratory, vascular and central nervous system diseases and disorders.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on SUCAMPO PHARMAC (SCMP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment